biotech Value proposition
Unmask Cancer, Elicit Immune Response
Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases.
A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response.
Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.
Glyco Immuno OncologyOriginal language
Unmask Cancer, Elicit Immune Response
Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases.
A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response.
Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.
Phost'in Therapeutics: unmask cancer, elicit immune response
Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases
https://www.phostin.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 BIC de Montpellier Government Administration | BIC de Montpellier Government Administration | Capitalistic Not partnership Not event 21 Apr 2020 27 Oct 2023 | | |